Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 7/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23104425 | 0.90 | CNR2 (0.39) | MAPKAPK2GSK3BDYRK1ADGAT1CNR2 | |
| SCHEMBL29736432 | 0.90 | CNR2 (0.39) | MAPKAPK2GSK3BDYRK1ADGAT1CNR2 | |
| SCHEMBL29845192 | 0.87 | CNR2 (0.40) | MAPKAPK2GSK3BDYRK1ACNR2CNR1 | |
| SCHEMBL28876620 | 0.87 | CNR2 (0.40) | MAPKAPK2GSK3BDYRK1ACNR2CNR1 | |
| SCHEMBL30172998 | 0.87 | SCN9A (0.35) | MAPKAPK2GSK3BDYRK1ADGAT1CNR2 | |
| SCHEMBL24992629 | 0.87 | MAPKAPK2 (0.36) | MAPKAPK2GSK3BDYRK1ADGAT1CNR2 | |
| SCHEMBL23104525 | 0.87 | CNR2 (0.40) | MAPKAPK2GSK3BDYRK1ACNR2CNR1 | |
| SCHEMBL24992618 | 0.87 | SCN9A (0.35) | MAPKAPK2GSK3BDYRK1ADGAT1CNR2 | |
| SCHEMBL30172986 | 0.87 | SCN9A (0.35) | MAPKAPK2GSK3BDYRK1ADGAT1CNR2 | |
| SCHEMBL23103813 | 0.79 | GSK3B (0.37) | MAPKAPK2GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011331-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2025-01-09 | — | — | US | disclosed |
| EP-4380565-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023015199-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023015199-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011331-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | MAPKAPK2 89/4885GSK3B 537/4885DYRK1A 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.